Dec. 2 at 6:21 PM
$LFMD $LFMD
Market is overreacting to the guidance cut. LifeMD sold a loss-making side business (WorkSimpli), improved EBITDA by ~90%, reduced debt, and is now a pure-play telehealth company in one of the fastest growing healthcare markets 🌍📈.
Analyst price targets are
$9–10 (some even
$15) vs. today’s ~
$3.5. That’s 2–3x upside potential. Stock is oversold (RSI <20) — looks more like an opportunity than a risk. 💎🙌